Stockscreener 앱 받기
9.81
0.20%
0.02
전일 마감가:
$9.79
열려 있는:
$9.81
하루 거래량:
774.17K
Relative Volume:
0.97
시가총액:
$403.35M
수익:
$128.29M
순이익/손실:
$-30.69M
주가수익비율:
-11.96
EPS:
-0.82
순현금흐름:
$-27.17M
1주 성능:
+10.97%
1개월 성능:
-23.12%
6개월 성능:
+34.75%
1년 성능:
-68.54%
1일 변동 폭
$9.61
$10.16
1주일 범위
$9.43
$10.96
52주 변동 폭
$6.32
$34.71
Rxsight Inc Stock (RXST) Company Profile
명칭
Rxsight Inc
전화
949-521-7822
주소
100 COLUMBIA STREET, ALISO VIEJO
RXST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
9.81 | 402.53M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-07-09 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-09 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 개시 | Piper Sandler | Neutral |
| 2025-04-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-04-04 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2025-04-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-10-29 | 개시 | Jefferies | Buy |
| 2024-08-20 | 재확인 | Needham | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-05-07 | 재확인 | BTIG Research | Buy |
| 2023-12-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 개시 | Morgan Stanley | Overweight |
| 2023-04-13 | 개시 | Oppenheimer | Outperform |
| 2022-12-12 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 개시 | Needham | Buy |
모두보기
Rxsight Inc 주식(RXST)의 최신 뉴스
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - FinancialContent
Institution Moves: What is RxSight Incs valuation compared to sectorTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
RxSight stock price target raised to $11.50 from $11.00 at Jefferies - Investing.com Canada
RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? - Nasdaq
RxSight Inc. (RXST) PT Raised to $11.50 at Jefferies - StreetInsider
RxSight Shows Growth in Preliminary Q4 and 2025 Results; Names Mark Wilterding as CFO - VisionMonday.com
RxSight Announces New CFO and Strong Preliminary Results - TipRanks
Stifel reiterates Hold rating on RxSight stock amid competition concerns By Investing.com - Investing.com Nigeria
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Stifel reiterates Hold rating on RxSight stock amid competition concerns - Investing.com
RxSight Up 11% on Preliminary Q4, Full Year Results - Orange County Business Journal
RxSight stock holds steady as UBS maintains Neutral rating ahead of conference - Investing.com Nigeria
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
RxSight (RXST) Reiterated at Neutral by UBS: 'Need More Regular Signs of Come-back' - StreetInsider
RxSight (RXST) Reiterated at Hold by Stifel Amid LAL, LDD Slowdown - StreetInsider
Benign Growth For RxSight, Inc. (NASDAQ:RXST) Underpins Stock's 30% Plummet - 富途牛牛
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
RxSight guides FY revenue above previous estimates, names new CFO - MSN
RxSight Sees Q4 Revenue Above View; Names Mark Wilterding CFO - Nasdaq
RxSight reports Q4 revenue of $32.6 million, exceeds 2025 guidance - Investing.com
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer - The Manila Times
RxSight, Inc. Reports Preliminary Financial Results for Q4 and Full-Year 2025; Announces Appointment of New CFO - Quiver Quantitative
RxSight says Mark Wilterding appointed as CFO effective Jan 11, 2026 - marketscreener.com
RxSight Says Mark Wilterding Appointed As CFO Effective Jan 11, 2026 - TradingView — Track All Markets
Star Tribune - FinancialContent
RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026 - marketscreener.com
We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely - Sahm
RxSight, Inc. (RXST) Investor Outlook: A Close Look At Its 7.98% Potential Upside - DirectorsTalk Interviews
RxSight down on CFO transition - MSN
Is RxSight Inc. stock dividend yield sustainableJuly 2025 Institutional & Stepwise Entry/Exit Trade Alerts - Улправда
Is RxSight Inc. stock trading at a premium valuation2025 Fundamental Recap & Real-Time Buy Signal Alerts - Улправда
Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - marketscreener.com
Will RxSight Inc. stock outperform international peers2026 world cup usa national team group stage playmakers possession football tactical prediction tactical review - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. ... - Bluefield Daily Telegraph
Looking At The Narrative For RxSight (RXST) After A Better Than Feared Quarter - Yahoo Finance
RxSight CFO Shelley Thunen to Step Down - Orange County Business Journal
Income Plays: Will RxSight Inc stock outperform value stocksEarnings Growth Summary & Low Risk High Win Rate Picks - moha.gov.vn
RxSight director sells $108,618 in common stock - MSN
Trading the Move, Not the Narrative: (RXST) Edition - Stock Traders Daily
RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference - The Manila Times
WaterWorldRxSight, Inc. to Present at the J.P. Morgan Healthcare Conference - FinancialContent
RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
RxSight, Inc. (RXST) Misses Q4 Earnings Estimates - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Shareholders to Reach Out - ACCESS Newswire
Institutional Owners May Take Dramatic Actions as RxSight, Inc.'s (NASDAQ:RXST) Recent 13% Drop Adds to One-year Losses - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
RxSight, Inc. Announces Transition of Chief Financial Officer Shelley Thunen - VisionMonday.com
RxSight enters transition agreement with outgoing CFO Shelley Thunen By Investing.com - Investing.com Nigeria
Rxsight Inc (RXST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
1.96%
자본화:
|
볼륨(24시간):